Please assess the completion status of the following clinical trial:

Trial Title: TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients meeting criteria for symptomatic myeloma~2. Patients who have progressive myeloma following initial induction (patients may have received any number of treatment regimens including prior autologous transplant)~3. Patient age 18-75 years at time of enrollment~4. Karnofsky performance status of ≥70~5. Cardiac function: LVEF \>40%~6. Hepatic: Bilirubin \<2x upper limit of normal and ALT and AST \< 2.5x the upper limit of normal~7. Renal: Creatinine clearance of \>30mL/min, estimated or calculated~8. Pulmonary: DLCO, FEV1, FVC \>50% of predicted (after correction for hemoglobin)~Exclusion Criteria:~1. Patients with diagnosis of plasma cell leukemia~2. Patients with truly non secretory myeloma (patients with light chain disease are eligible)~3. Pregnant or breast-feeding~4. Uncontrolled viral, fungal or bacterial infection Note: Infection is permitted if there is evidence of response to medication. Eligibility of HIV infected patients will be determined on a case-by-case basis.~5. Patients who have undergone prior allogeneic stem cell transplant~6. Prior solid organ transplant~7. Patients receiving prior radiation to more than 20% of bone marrow containing areas

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1Total Marrow Irradiation (TMI) 3Gy (Type: EXPERIMENTAL): 3Gy with standard high dose melphalan prior to autologous stem cell rescue
- Cohort 2 Total Marrow Irradiation (TMI) 6Gy (Type: EXPERIMENTAL): 6Gy with standard high dose melphalan prior to autologous stem cell rescue
- Cohort 3 Total Marrow Irradiation (TMI) 9Gy (Type: EXPERIMENTAL): 9Gy with standard high dose melphalan prior to autologous stem cell rescue

Based on this trial design, predict the completion outcome and termination type (if applicable).